{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:37:43Z","timestamp":1792715863829,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.esmoop.2026.108543","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:11:03Z","timestamp":1789157463000},"page":"108543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7109-2429","authenticated-orcid":false,"given":"A.","family":"Cigliola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.A.","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Robesti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fallara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-1776","authenticated-orcid":false,"given":"C.","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-7177","authenticated-orcid":false,"given":"G.","family":"Musso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-2338","authenticated-orcid":false,"given":"V.","family":"Tateo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Piacentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4987-7898","authenticated-orcid":false,"given":"A.","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Disabato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3515-483X","authenticated-orcid":false,"given":"C.","family":"Piccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Rosiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9225-1795","authenticated-orcid":false,"given":"U.","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmoop.2026.108543_bib1","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2022.08.019","article-title":"Epidemiology of renal cell carcinoma: 2022 update","volume":"82","author":"Bukavina","year":"2022","journal-title":"Eur Urol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.108543_bib2","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.19.00107","article-title":"Predicting renal cancer recurrence: defining limitations of existing prognostic models with prospective trial-based validation","volume":"37","author":"Correa","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2026.108543_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11934-017-0661-3","article-title":"Recurrence in localized renal cell carcinoma: a systematic review of contemporary data","volume":"18","author":"Speed","year":"2017","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.esmoop.2026.108543_bib4","series-title":"NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer","year":"2025"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108543_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology Guidelines on Renal Cell Carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.108543_bib6","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2026.108543_bib7","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"10379","key":"10.1016\/j.esmoop.2026.108543_bib8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.esmoop.2026.108543_bib9","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s00345-022-04153-6","article-title":"How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?","volume":"40","author":"Fallara","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.esmoop.2026.108543_bib10","first-page":"2075","article-title":"Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials","volume":"45","author":"Kent","year":"2016","journal-title":"Int J Epidemiol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.108543_bib11","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","article-title":"Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis","volume":"27","author":"Choueiri","year":"2021","journal-title":"Nat Med"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2026.108543_bib12","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2019.37.7_suppl.558","article-title":"Results from a phase I expansion cohort of the first-in-class oral HIF-2\u03b1 inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC","volume":"37","author":"Rini","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108543_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa2518245","article-title":"Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma","volume":"395","author":"Choueiri","year":"2026","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2026.108543_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.esmoop.2026.108543_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.955894","article-title":"Immunotherapy in advanced kidney cancer: an alternative meta-analytic method using reconstructed survival data in case of proportional hazard assumption violation","volume":"12","author":"Nocera","year":"2022","journal-title":"Front Oncol"},{"issue":"15","key":"10.1016\/j.esmoop.2026.108543_bib16","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/cncr.34255","article-title":"Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: the potential impact of informative censoring","volume":"128","author":"Martini","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.108543_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102360","article-title":"Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: a systematic review and meta-analysis","volume":"104","author":"Martini","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.esmoop.2026.108543_bib18","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.108543_bib19","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14796694.2025.2464485","article-title":"Oncologists\u2019 and urologists\u2019 preferences for adjuvant therapy in renal cell carcinoma: a discrete-choice experiment","volume":"21","author":"Vass","year":"2025","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2026.108543_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/annonc\/mdz039","article-title":"Making adjuvant therapy decisions with uncertain data","volume":"30","author":"Gyawali","year":"2019","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926024889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926024889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:41:00Z","timestamp":1792712460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926024889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2059702926024889"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108543","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant pembrolizumab plus belzutifan versus placebo in clear cell renal cell carcinoma: a reconstructed survival data analysis of the KEYNOTE-564 and the LITESPARK-022 trials","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.108543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"108543"}}